{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityComment":"Hospital stay will be compared between groups using the Wilcoxon rank sum test with a p value of 0.05.","nonInferiorityType":"NON_INFERIORITY","pValue":"0.05","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22","upperLimit":"89","value":"31"},{"groupId":"OG001","lowerLimit":"20","upperLimit":"55","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"Hospital stay will be compared between patients in groups A and B using the Wilcoxon rank sum test.","dispersionType":"Full Range","groups":[{"description":"Participants receive tacrolimus IV over 24 hours beginning on day -1 (or tacrolimus orally beginning on day -3) and then PO BID after engraftment with a taper from day 100 to day 180 (in the absence of GVHD). Patients also receive methotrexate IV on days 1, 3, 6, and 11.\n\ntacrolimus: Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL\n\nmethotrexate: MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient \\< 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.","id":"OG000","title":"Group A (Tacrolimus, Methotrexate)"},{"description":"Patients receive tacrolimus as in group A and methotrexate (low dose) IV on days 1, 3, and 6. Patients also receive oral mycophenolate mofetil BID beginning on day 1, with a taper from day 45 to day 100 (in the absence of GVHD).\n\ntacrolimus: Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL\n\nMycophenolate mofetil: Patients will receive Mycophenolate beginning on day +1. Patients \\>40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients \\< 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol\n\nMethotrexate (low dose): MTX 5mg/m2 IV on day +1, +3, +6. If patient\\<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.","id":"OG001","title":"Group B (Tacrolimus, Methotrexate, Mycophenolate Mofetil)"}],"paramType":"MEDIAN","populationDescription":"participants who completed the study","reportingStatus":"POSTED","timeFrame":"Date of transplant to date of discharge, assessed up to 1 year","title":"Length of Hospitalization","type":"SECONDARY","unitOfMeasure":"days"}